Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (664)	5/21/2002 3:22:32 AM
From: nigel bates	Respond to of 675

Is The Independent generally reliable? In as far as any newspaper is, they are pretty good on biotech. nig

To: Mike McFarland who wrote (664)	5/31/2002 6:27:26 AM
From: nigel bates	Read Replies (1) \| Respond to of 675

CeNeS Announces Disposal of its Cognitive Testing Division Cambridge, UK, 31 May 2002 - CeNeS Pharmaceuticals plc (LSE: CEN.L - news) today announced the spin-out of its cognitive testing division as part of the ongoing restructuring programme, which was initiated in October 2001. CeNeS' cognition division has been sold to its management team funded by a syndicate of investors advised by Yorkshire Fund Managers. The new company will be called Cambridge Cognition. Under the terms of the agreement CeNeS will receive up to £1 million. Of this total consideration, £700,000 is in upfront and stage payments and a further £300,000 is dependent on certain milestones. Under the restructuring plan, CeNeS is focusing on its core business in the development, marketing and sale of drugs for the treatment of disorders of the CNS and pain, which has entailed reducing or disposing of non-core activities. CeNeS' cognition division was acquired in early 1997 and achieved revenues of over £1 million in 2001.The current management team was assembled in mid-2001 in preparation for the planned disposal that has completed today. Commenting on the disposal, Neil Clark, Chief Operating Officer and Finance Director of CeNeS, said:- "The disposal of the cognition division is another successful step under our restructuring programme. CeNeS' board started the planned spin out process in mid-2001 and we are pleased that the cognition division's management have obtained backing from a syndicate of investors who will support the further growth of the company and validation of the cognitive testing expertise."...